Columbia-SDP Oncology Research Alliance

The Columbia - SDP Oncology Research Alliance ran from 2019-2022 and is now dormant.

This collaboration stimulated research and development in the field of oncology through collaborative, Columbia investigator initiated projects.

Questions? Please reach out to Devin Jones at [email protected].

CLICK HERE to read more about the funded teams.

About Sumitomo Dainippon Pharma Oncology

Sumitomo Dainippon Pharma Oncology, Inc., is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. As a global oncology organization with teams in the U.S. and Japan, SDP Oncology is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. The company's robust and diverse pipeline of preclinical and advanced-stage assets spans multiple areas, including oncogenic pathways, survival mechanisms and novel protein interactions, which aim to address unmet clinical needs in oncology.

For more information, visit